» Articles » PMID: 31991800

Zebrafish Avatars Towards Personalized Medicine-A Comparative Review Between Avatar Models

Overview
Journal Cells
Publisher MDPI
Date 2020 Jan 30
PMID 31991800
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer frequency and prevalence have been increasing in the past decades, with devastating impacts on patients and their families. Despite the great advances in targeted approaches, there is still a lack of methods to predict individual patient responses, and therefore treatments are tailored according to average response rates. "Omics" approaches are used for patient stratification and choice of therapeutic options towards a more precise medicine. These methods, however, do not consider all genetic and non-genetic dynamic interactions that occur upon drug treatment. Therefore, the need to directly challenge patient cells in a personalized manner remains. The present review addresses the state of the art of patient-derived and models, from organoids to mouse and zebrafish Avatars. The predictive power of each model based on the retrospective correlation with the patient clinical outcome will be considered. Finally, the review is focused on the emerging zebrafish Avatars and their unique characteristics allowing a fast analysis of local and systemic effects of drug treatments at the single-cell level. We also address the technical challenges that the field has yet to overcome.

Citing Articles

The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment.

Kokori E, Olatunji G, Ogieuhi I, Ajayi Y, Akinmoju O, Akinboade A Int J Clin Oncol. 2025; .

PMID: 40080361 DOI: 10.1007/s10147-025-02736-y.


Small Fish, Big Answers: Zebrafish and the Molecular Drivers of Metastasis.

Martinez-Lopez M, Lopez-Gil J Int J Mol Sci. 2025; 26(3).

PMID: 39940643 PMC: 11817282. DOI: 10.3390/ijms26030871.


Phenotypically plastic drug-resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model.

Baykal S, Yuce Z, Ozhan G J Cell Mol Med. 2024; 28(19):e70105.

PMID: 39392217 PMC: 11467800. DOI: 10.1111/jcmm.70105.


Diverse Engraftment Capability of Neuroblastoma Cell Lines in Zebrafish Larvae.

Lawrence J, Tan S, Kim D, Tan K, Schroeder S, Yeo K Zebrafish. 2024; 21(6):385-393.

PMID: 39316469 PMC: 11876807. DOI: 10.1089/zeb.2024.0160.


Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer.

Costa B, Estrada M, Gomes A, Fernandez L, Azevedo J, Povoa V Nat Commun. 2024; 15(1):4771.

PMID: 38839755 PMC: 11153622. DOI: 10.1038/s41467-024-49051-0.


References
1.
Tiefenbacher A, Pirker R . EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome. J Thorac Dis. 2017; 9(11):4208-4211. PMC: 5720983. DOI: 10.21037/jtd.2017.10.02. View

2.
Harris A, Lee S, Dawson L, Marlow L, Edenfield B, Durham W . Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF -mutant melanoma. Oncotarget. 2018; 9(13):10905-10919. PMC: 5834273. DOI: 10.18632/oncotarget.23649. View

3.
Kenny P, Lee G, Myers C, Neve R, Semeiks J, Spellman P . The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2008; 1(1):84-96. PMC: 2391005. DOI: 10.1016/j.molonc.2007.02.004. View

4.
Montero J, Sarosiek K, DeAngelo J, Maertens O, Ryan J, Ercan D . Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015; 160(5):977-989. PMC: 4391197. DOI: 10.1016/j.cell.2015.01.042. View

5.
Miyoshi H, Maekawa H, Kakizaki F, Yamaura T, Kawada K, Sakai Y . An improved method for culturing patient-derived colorectal cancer spheroids. Oncotarget. 2018; 9(31):21950-21964. PMC: 5955161. DOI: 10.18632/oncotarget.25134. View